**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 87787

**Manuscript Type:** OPINION REVIEW

**Gut-targeted therapies for type 2 diabetes mellitus: A review**

Xu TC *et al*. Gut-targeted therapies for T2DM

Tian-Cheng Xu, Yun Liu, Zhi Yu, Bin Xu

**Tian-Cheng Xu, Yun Liu, Zhi Yu, Bin Xu,** Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China

**Co-first authors:** Tian-Cheng Xu and Yun Liu.

**Co-corresponding authors:** Zhi Yu and Bin Xu.

**Author contributions:** Yu Z and Xu B conceptualized and designed the research; Xu TC and Liu Y wrote the paper. Xu TC searched the literature, revised and submitted the early version of the manuscript with the focus on gut-targeted therapies for type 2 diabetes mellitus; Xu TC and Liu Y collaborated closely on basic research related to this review, which inspired the writing of this review; Both authors have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-first authors of the paper; Yu Z and Xu B have played important and indispensable roles in the data interpretation and manuscript preparation as the co-corresponding authors; All the authors contributed to the initial writing and have read and approved the final manuscript.

**Supported by** the National Natural Science Foundation of China, No. 82074532, No. 82305376, and No. 81873238; the Open Projects of the Discipline of Chinese Medicine of Nanjing University of Chinese Medicine supported by the Subject of Academic Priority Discipline of Jiangsu Higher Education Institutions, No. ZYX03KF012; and the Postgraduate Research & Practice Innovation Program of Jiangsu Province, No. KYCX22\_1963.

**Corresponding author: Bin Xu, MD, PhD, Director, Professor,** Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, No. 138 Xianlin Road, Nanjing 210023, Jiangsu Province, China. xubin@njucm.edu.cn

**Received:** August 27, 2023

**Revised:** November 24, 2023

**Accepted:** December 18, 2023

**Published online:**

**Abstract**

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia and insulin resistance. The global prevalence of T2DM has reached epidemic proportions, affecting approximately 463 million adults worldwide in 2019. Current treatments for T2DM include lifestyle modifications, oral antidiabetic agents, and insulin therapy. However, these therapies may carry side effects and fail to achieve optimal glycemic control in some patients. Therefore, there is a growing interest in the role of gut microbiota and more gut-targeted therapies in the management of T2DM. The gut microbiota, which refers to the community of microorganisms that inhabit the human gut, has been shown to play a crucial role in the regulation of glucose metabolism and insulin sensitivity. Alterations in gut microbiota composition and diversity have been observed in T2DM patients, with a reduction in beneficial bacteria and an increase in pathogenic bacteria. This dysbiosis may contribute to the pathogenesis of the disease by promoting inflammation and impairing gut barrier function. Several gut-targeted therapies have been developed to modulate the gut microbiota and improve glycemic control in T2DM. One potential approach is the use of probiotics, which are live microorganisms that confer health benefits to the host when administered in adequate amounts. Several randomized controlled trials have demonstrated that certain probiotics, such as Lactobacillus and Bifidobacterium species, can improve glycemic control and insulin sensitivity in T2DM patients. Mechanisms may include the production of short-chain fatty acids, the improvement of gut barrier function, and the reduction of inflammation. Another gut-targeted therapy is fecal microbiota transplantation (FMT), which involves the transfer of fecal material from a healthy donor to a recipient. FMT has been used successfully in the treatment of *Clostridioides difficile* infection and is now being investigated as a potential therapy for T2DM. A recent randomized controlled trial showed that FMT from lean donors improved glucose metabolism and insulin sensitivity in T2DM patients with obesity. However, FMT carries potential risks, including transmission of infectious agents and alterations in the recipient's gut microbiota that may be undesirable. In addition to probiotics and FMT, other gut-targeted therapies are being investigated for the management of T2DM, such as prebiotics, synbiotics, and postbiotics. Prebiotics are dietary fibers that promote the growth of beneficial gut bacteria, while synbiotics combine probiotics and prebiotics. Postbiotics refer to the metabolic products of probiotics that may have beneficial effects on the host. The NIH SPARC program, or the Stimulating Peripheral Activity to Relieve Conditions, is a research initiative aimed at developing new therapies for a variety of health conditions, including T2DM. The SPARC program focuses on using electrical stimulation to activate peripheral nerves and organs, in order to regulate glucose levels in the body. The goal of this approach is to develop targeted, non-invasive therapies that can help patients better manage their diabetes. One promising area of research within the SPARC program is the use of electrical stimulation to activate the vagus nerve, which plays an important role in regulating glucose metabolism. Studies have shown that vagus nerve stimulation can improve insulin sensitivity and lower blood glucose levels in patients with T2DM. Gut-targeted therapies, such as probiotics and FMT, have shown potential for improving glycemic control and insulin sensitivity in T2DM patients. However, further research is needed to determine the optimal dose, duration, and safety of these therapies.

**Key Words:** Type 2 diabetes mellitus; Gastroenterology; Bacteria; Implanted device

Xu TC, Liu Y, Yu Z, Xu B. Gut-targeted therapies for type 2 diabetes mellitus: A review. *World J Clin Cases* 2023; In press

**Core Tip:** Gut-targeted therapies, such as probiotics and fecal microbiota transplantation, have shown potential for improving glycemic control and insulin sensitivity in type 2 diabetes mellitus patients. However, further research is needed to determine the optimal dose, duration, and safety of these therapies. Although many invention patents have been formed and put into clinical practice for the treatment of hypoglycemia targeting the intestine, the increasing results of basic research still mean greater room for progress.

**INTRODUCTION**

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder, characterized by high blood sugar levels resulting from insulin resistance or impaired insulin secretion. It has become a worldwide epidemic with significant public health implications. According to the International Diabetes Federation, in 2019, approximately 463 million adults (20-79 years) had diabetes, and more than 90% of those cases were T2DM. It is assumed that this number will rise to 700 million by 2045[1].

The high prevalence of T2DM can be attributed to several reasons[2]. Sedentary lifestyle, unhealthy dietary patterns such as a Western diet, and increasing obesity rates are major contributors. Urbanization and globalization have led to increased consumption of calorie-dense, processed foods and reduced physical activity. Additionally, aging populations, coupled with longer life expectancies, contribute to the rising prevalence as T2DM is more common in older individuals. The increasing aging population will lead to further deterioration of the situation, and treatment for the elderly is more limited, so early detection and prevention are more important.

In summary, T2DM is a global public health challenge with an increasing prevalence worldwide. The multifactorial nature of its etiology requires comprehensive strategies for prevention, early detection, and effective management. Promoting healthy lifestyles, raising awareness, improving access to healthcare, and addressing social determinants of health are essential in curbing the T2DM epidemic[3]. Considering that T2DM is a disease highly associated with intestinal absorption and intestinal flora, this article will focus on the research progress in this area and discuss future therapies. Given the extensive reviews on academic papers focused on T2DM, the novelty of this article lies in the discussion of invention patents related to the gut-based treatment of T2DM, which is the highlight and distinctive feature of this article.

**IMPLANTED ELECTRONIC DEVICES IN THE INTESTINE FOR THE TREATMENT OF T2DM**

Implanting electronic devices in the intestine is an emerging field that holds immense potential for improving the management of T2DM. These devices, including those commonly known as "smart pills" or "digestible sensors"[4], can be ingested orally and provide real-time monitoring and therapeutic interventions within the gastrointestinal tract[5,6]. Although the field of implantable electronic devices for T2DM treatment is still in its early stages, preliminary studies have demonstrated their safety and efficacy. With further advancements in miniaturization, wireless communication, and material technology[7,8], these devices are poised to revolutionize the management of T2DM by providing personalized, targeted therapy. Additionally, more devices of this kind are implanted with surgery as shown in Table 1[9-13].

Implantable gastrointestinal stimulation devices used for T2DM treatment have the following characteristics: they are often driven by electricity and directly or indirectly stimulate the intestinal nerves or alter the intestinal morphology to affect local and even systemic hormone secretion[14,15]. The advantages of these devices lie in their relatively clear treatment mechanisms, including regulation of hormone homeostasis led by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)[16,17], as well as neuro-immune homeostasis composed of C-fibers and A-fibers[18,19]. These types of gastrointestinal electrical stimulation devices therefore have relatively clear target audiences and service objects, and are actively chosen by doctors and hospitals due to their clear mechanisms. However, these devices have significant drawbacks for patients. Firstly, compared to oral hypoglycemic drugs, implantable gastrointestinal stimulation devices used for T2DM treatment often require invasive surgery for implantation, which hinders more patients from choosing this type of device even if their blood glucose control abilities are similar[20]. Additionally, since these devices rely on electrical power, similar to devices like pacemakers, gastrointestinal stimulation devices also need to be replaced regularly, which can discourage patients from choosing them, even if the replacement cycle is 5 to 10 years[21].

Based on the above discussion and considering the contents of Table 1, we believe that the future development trends of these devices mainly involve three aspects. Firstly, miniaturization of the devices. Whether driven by the rapid progress of the electronics industry or the clinical needs of patients, implantable gastrointestinal stimulation devices used for T2DM treatment will develop towards miniaturization, especially devices that stimulate the intestinal and pancreatic nerves. Furthermore, due to the further precision of their therapeutic targets, the degree of miniaturization will continue to increase. Secondly, diversification of treatment methods. Despite having clear targets, considering the diversity of glucose-regulating hormones in the intestines, as shown in Table 1 with multiple devices involved, future gastrointestinal stimulation devices may use multiple methods such as mechanical force, electric current, and infrared to stimulate the intestines and regulate blood glucose levels[22]. Based on the higher level of technological integration symbolized by the miniaturization of the devices, future gastrointestinal stimulation devices may also include more than one physical stimulation method simultaneously, occupying less space and providing patients with more treatment options. In fact, this trend can already be seen in Table 1, as some devices are no longer standalone gastrointestinal stimulation devices, but rather a treatment system. Lastly, one of the future directions will be electrical stimulation devices with personalized feedback[23,24]. Whether it is physical mechanical pressure stimulation or stimulation from sound waves and light waves, the core therapeutic goal is to control blood glucose within the ideal range. However, the degree of control is not only based on the requirements of disease treatment guidelines, but also revolves around the individual characteristics of patients, especially as most T2DM patients are elderly individuals with multiple chronic diseases. Hypoglycemia can even be life-threatening, and since the intestine serves as a storage and digestion organ for food, integrating blood glucose monitoring devices and using device feedback to prevent excessive hypoglycemia is particularly necessary[25,26]. In this sense, the advantages of electronic gastrointestinal stimulation devices become very apparent, as they contain a power source that not only drives the gastrointestinal stimulation device itself but also ensures the energy supply for blood glucose monitoring devices and related chips[27,28].

**TREATMENT OF T2DM WITH INTESTINAL MICROFLORA INTERVENTION**

Therapies for T2DM starting from the gut include not only treatment devices represented by electrical stimulation devices but also another major category known as gut microbiota therapy. Intervening in blood glucose and lipid metabolism through the gut microbiota has been the focus of over a decade of clinical practice and extensive basic research. A series of studies on regulating the microbiota for glycemic control has successfully achieved the translation from the laboratory to clinical settings, covering different levels from food and health products to pharmaceuticals[29]. For example, Chlorella may play an important role in improving the overall condition of diabetic patients by restoring the function of pancreatic insulin-secreting cells[30]. Combined therapy with pioglitazone and bone marrow cells transplantation could potentiate the protective benefit of mesenchymal stem cells against diabetes and cardiac damage[31]. This approach has extensively covered potential user groups and continues to iterate and make progress. Table 2 presents some representative achievements in this field[32-35].

As shown in Table 2, intervention of T2DM through gut microbiota has presented more systematic characteristics by utilizing the gut as a medium. Firstly, the treatment of gut microbiota no longer focuses solely on the simple transplantation and replication of healthy microbiota, but takes into consideration relevant associated factors[36]. Even though existing sequencing technologies can identify low-abundance microbial communities, current studies and related products have realized the importance of reconstructing a normal microbial habitat, which is superior to directly consuming various formulations of healthy microbiota. In terms of therapeutic effects, techniques including fecal microbiota transplantation (FMT) have gradually helped T2DM patients to overcome insulin dependence. Furthermore, the selection of microbial communities has become increasingly precise. Secondly, thanks to the achievements of genetic engineering, engineered bacteria rather than natural bacteria have been increasingly applied in the treatment of T2DM[37]. Although the short-term cost of this therapy is high, with the scaling-up of applications and the global sharing of treatment costs, more precise and personalized microbial therapy will become the main trend. In addition, in the manufacturing process of microbial communities, more achievements in bionics have been systematically employed[38]. For example, devices for culturing microbial communities that mimic the structure of the human gut have gradually started to be utilized[39,40].

The use of interventions to improve the gut microbiota as a means of treating T2DM has become a long-term clinical practice. Two main approaches have emerged in relation to this intervention. One approach involves directly altering the composition of the gut microbiota by consuming various types of synthetic or cultivated gut microbiota preparations or live bacteria[41,42]. The other approach involves obtaining appropriate strains of bacteria through FMT from a relatively defined donor. In the practical application of these approaches, it has been found that effective gut interventions for T2DM, which primarily involve manipulating the gut microbiota, have specific requirements regarding the types and proportions of microbiota, as well as the administration route, dosage form, and potential need for concomitant use of antibiotics[43,44]. Furthermore, due to differing regulations of food and drug administrations across countries, products related to gut interventions may take the form of pharmaceuticals, foods, or dietary supplements. However, changes in dosage form or microbiota strains may also impact the efficacy of these interventions to some extent, which is an inevitable issue that various medical research studies face when translating to routine clinical practice in accordance with specific national legal and regulatory requirements[45,46].

**THE FUTURE OF GUT-INTERVENTION THERAPIES FOR T2DM**

In summary, T2DM is a metabolic disorder characterized by insulin resistance and impaired glucose regulation. With the increasing prevalence of T2DM worldwide, there is a growing need for innovative treatment strategies to effectively manage this chronic condition. One emerging field of research is gut-intervention therapies, which involve modulating the composition and activity of the gut microbiota to improve metabolic health[47]. This approach has shown promising results in preclinical and clinical studies, and the future development of gut-intervention therapies holds great potential in the management of T2DM.

One of the future trends in gut-intervention therapies for T2DM is the identification of specific gut microbiota signatures associated with the disease[48]. Research has shown that individuals with T2DM have distinct gut microbial profiles compared to healthy individuals. By further characterizing these microbial signatures, scientists can develop targeted interventions that aim to restore the balance of the gut microbiota in individuals with T2DM. This may involve the use of probiotics, prebiotics, or even FMT to introduce specific beneficial bacteria or microbial metabolites into the gut ecosystem[49].

Another trend in the future development of gut-intervention therapies is the utilization of advanced technologies to monitor and assess the gut microbiota. Advances in DNA sequencing and bioinformatics have enabled researchers to more accurately identify and quantify the microbial composition in the gut[50]. This allows for a more personalized approach to gut-intervention therapies, as individuals can be classified into distinct microbial clusters based on their gut microbiota profiles. Such personalized treatments could have improved efficacy and reduced side effects, as they target the specific imbalances in the gut microbiota that are contributing to T2DM.

The incorporation of dietary modifications alongside gut-intervention therapies is also seen as a potential future trend. It is widely recognized that a healthy diet plays a crucial role in the management of T2DM. Certain dietary components, such as fiber, polyphenols, and omega-3 fatty acids, have been shown to promote the growth of beneficial gut bacteria and enhance metabolic health[51]. Therefore, combining gut-intervention therapies with personalized dietary recommendations may optimize treatment outcomes. This could involve the development of tailored dietary plans that aim to improve both gut microbiota composition and metabolic parameters in individuals with T2DM.

In a sense, through the overview of this article, we also consider a possibility that the combination of electrical stimulation devices and microbiota therapy is inevitable as the feasibility of miniaturization technology continues to improve. Blood glucose regulation is an extremely complex process, influenced by rhythmic daily behaviors such as eating and sleeping, as well as fluctuating factors such as emotions. The seemingly perfect insulin therapy cannot be the sole treatment for T2DM. Stimulating a single target often implies potential and cumulative side effects, which have become evident in patients receiving long-term insulin treatment. In this sense, it is particularly necessary to adopt a multi-target strategy for treatment, with an approach through the gut microbiota.

Additionally, the future development of gut-intervention therapies may involve the use of microbial-based therapeutics. This includes the development of engineered probiotics or microbial consortia that can deliver specific therapeutic functions to the gut[52,53]. For example, scientists are exploring the use of genetically modified probiotic strains that can produce beneficial metabolites or modulate the host immune response. Such microbial-based therapeutics could provide a more targeted and sustainable approach to T2DM treatment, as they can persistently colonize the gut and exert long-term beneficial effects.

**CONCLUSION**

In conclusion, the future development of gut-intervention therapies for T2DM holds significant promise in improving the management of this chronic condition. The identification of specific gut microbiota signatures associated with T2DM, advancements in gut microbiota monitoring technologies, incorporation of dietary modifications, and the use of microbial-based therapeutics are some of the key trends that will shape the field. As research in this area continues to evolve, the potential for personalized and effective gut-intervention therapies for T2DM is expected to increase, ultimately benefiting individuals living with this metabolic disorder.

**REFERENCES**

1 **Saeedi P**, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract* 2019; **157**: 107843 [PMID: 31518657 DOI: 10.1016/j.diabres.2019.107843]

2 **Fareed M,** Salam N, Khoja AT, Mahmoud MA, Ahamed l M. Life style related risk factors of type 2 diabetes mellitus and its increased prevalence in Saudi Arabia: A brief review. *Int J Med Res Health* 2017; **6:** 125-132. Available from: https://www.ijmrhs.com/abstract/Life-style-related-risk-factors-of-type-2-diabetes-mellitus-and-its-increased-prevalence-in-saudi-arabia-a-brief-review-12047.html

3 **Joseph JJ**, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH, Sperling LS; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. *Circulation* 2022; **145**: e722-e759 [PMID: 35000404 DOI: 10.1161/CIR.0000000000001040]

4 **Inami A,** Iyama E, Itai S, Hiroaki Onoe. Wireless and battery-free digestible sensor for intestinal bacteria monitoring[C]//24th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2020. *CBMS* **2020:** 575-576. Available from: https://keio.elsevierpure.com/en/publications/wireless-and-battery-free-digestible-sensor-for-intestinal-bacter

5 **Kadirvel V,** Mithulesh TV, Hemamalini S, Kulathooran R. Edible Electronic Medical Devices and their Potential Application in the Medical Field: A Review. Advancement, Opportunities, and Practices in Telehealth Technology, **2022:** 1-29. Available from: https://www.igi-global.com/chapter/edible-electronic-medical-devices-and-their-potential-application-in-the-medical--field/312079

6 **Chahid Y,** Benabdellah M, Kannouf N. Smart hospitals and cyber security attacks[C]//International Conference on Digital Technologies and Applications. Cham: Springer International Publishing, **2021:** 291-300 [DOI: 10.1007/978-3-030-73882-2\_27]

7 **La TG,** Le LH. Flexible and wearable ultrasound device for medical applications: A review on materials, structural designs, and current challenges. *Adv Mater Technol* 2022; **7:** 2100798 [DOI: 10.1002/admt.202100798]

8 **Tricoli A,** Nasiri N, De S. Wearable and miniaturized sensor technologies for personalized and preventive medicine. *Adv Funct Mater* 2017; **27:** 1605271 [DOI: 10.1002/adfm.201605271]

9 **Barham K,** Abu Dayyeh Samuel J, Asirvatham Christopher V.Desimone, Electroporation for obesity or diabetes treatment, 2016, AU Patent. AU2016335755B2. Available from: https://www.zhangqiaokeyan.com/patent-detail/06130406683961.html

10 **Dann M,** Butters J, Fluet G, Lee G, Kagan J, Swain P, von Hoffmann G, Wright J, Devices and methods for endolumenal gastrointestinal bypass, 2020 US Patent, US20200179149A1. Available from: https://www.zhangqiaokeyan.com/patent-detail/06130437425902.html

11 **Arnold W.** Thornton, Dennis Dong-Won Kim, Mark B. Knudson, Katherine S. Tweden, Richard R. Wilson, Methods and systems for glucose regulation, 2021, US Patent, US20210046313A1. Available from: https://patents.google.com/patent/US10722714B2/en?q=(Methods+and+systems+for+glucose+regulation)&oq=Methods+and+systems+for+glucose+regulation

12 **Pasricha P,** Liu L. Treatments for Diabetes Mellitus and Obesity, 2020, US Patent, US20200155218A1. Available from: https://patents.google.com/patent/US20200155218A1/en?q=(Treatments+for+Diabetes+Mellitus+and+Obesity)&oq=Treatments+for+Diabetes+Mellitus+and+Obesity

13 **Oren IB,** Yaniv I, Wolf T, Herschkovitz A. Methods and systems for blocking neural activity in an organ of a subject, preferably in the small intestine or the duodenum,2020, US Patent, US10537387B2. Available from: https://patents.google.com/patent/US10537387B2/en

14 **Muszyński S**, Hułas-Stasiak M, Dobrowolski P, Arciszewski MB, Hiżewska L, Donaldson J, Mozel S, Rycerz K, Kapica M, Puzio I, Tomaszewska E. Maternal acrylamide exposure changes intestinal epithelium, immunolocalization of leptin and ghrelin and their receptors, and gut barrier in weaned offspring. *Sci Rep* 2023; **13**: 10286 [PMID: 37355724 DOI: 10.1038/s41598-023-37590-3]

15 **Wei L**, Ji L, Miao Y, Han X, Li Y, Wang Z, Fu J, Guo L, Su Y, Zhang Y. Constipation in DM are associated with both poor glycemic control and diabetic complications: Current status and future directions. *Biomed Pharmacother* 2023; **165**: 115202 [PMID: 37506579 DOI: 10.1016/j.biopha.2023.115202]

16 **Scheen AJ**. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. *Ann Endocrinol (Paris)* 2023; **84**: 316-321 [PMID: 36639119 DOI: 10.1016/j.ando.2022.12.423]

17 **Rosenstock J**, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. *Lancet* 2023; **402**: 529-544 [PMID: 37385280 DOI: 10.1016/S0140-6736(23)01053-X]

18 **Mooshage CM**, Schimpfle L, Kender Z, Tsilingiris D, Aziz-Safaie T, Hohmann A, Szendroedi J, Nawroth P, Sturm V, Heiland S, Bendszus M, Kopf S, Kurz FT, Jende JME. Association of Small Fiber Function with Microvascular Perfusion of Peripheral Nerves in Patients with Type 2 Diabetes: Study using Quantitative Sensory Testing and Magnetic Resonance Neurography. *Clin Neuroradiol* 2023 [PMID: 37548682 DOI: 10.1007/s00062-023-01328-5]

19 **Kaur M**, Misra S, Swarnkar P, Patel P, Das Kurmi B, Das Gupta G, Singh A. Understanding the role of hyperglycemia and the molecular mechanism associated with diabetic neuropathy and possible therapeutic strategies. *Biochem Pharmacol* 2023; **215**: 115723 [PMID: 37536473 DOI: 10.1016/j.bcp.2023.115723]

20 **Łuniewski M**, Matyjaszek-Matuszek B, Lenart-Lipińska M. Diagnosis and Non-Invasive Treatment of Obesity in Adults with Type 2 Diabetes Mellitus: A Review of Guidelines. *J Clin Med* 2023; **12** [PMID: 37445466 DOI: 10.3390/jcm12134431]

21 **Rajagopalan H,** Caplan J, Craig M. Gardner J. Christopher Flaherty, Methods and systems for treating diabetes and related diseases and disorders, 2020, US Patent, US10869718B2. Available from: https://patents.google.com/patent/US10869718B2/en

22 **Mahapatra S,** Kumari R, Dkhar DS, Chandra P. Engineered Nanomaterial based Implantable MicroNanoelectrode for in vivo Analysis: Technological Advancement and Commercial Aspects. *Microchemical Journal* **2023:** 108431 [DOI: 10.1016/j.microc.2023.108431]

23 **Pfützner A**, Tencer B, Stamm B, Mehta M, Sharma P, Gilyazev R, Jensch H, Thomé N, Huth M. Miniaturization of an Osmotic Pressure-Based Glucose Sensor for Continuous Intraperitoneal and Subcutaneous Glucose Monitoring by Means of Nanotechnology. *Sensors (Basel)* 2023; **23** [PMID: 37177745 DOI: 10.3390/s23094541]

24 **Chmayssem A**, Nadolska M, Tubbs E, Sadowska K, Vadgma P, Shitanda I, Tsujimura S, Lattach Y, Peacock M, Tingry S, Marinesco S, Mailley P, Lablanche S, Benhamou PY, Zebda A. Insight into continuous glucose monitoring: from medical basics to commercialized devices. *Mikrochim Acta* 2023; **190**: 177 [PMID: 37022500 DOI: 10.1007/s00604-023-05743-w]

25 **Li J**, Liu J, Wu Z, Shang X, Li Y, Huo W, Huang X. Fully printed and self-compensated bioresorbable electrochemical devices based on galvanic coupling for continuous glucose monitoring. *Sci Adv* 2023; **9**: eadi3839 [PMID: 37467335 DOI: 10.1126/sciadv.adi3839]

26 **Yuan X**, Ouaskioud O, Yin X, Li C, Ma P, Yang Y, Yang PF, Xie L, Ren L. Epidermal Wearable Biosensors for the Continuous Monitoring of Biomarkers of Chronic Disease in Interstitial Fluid. *Micromachines (Basel)* 2023; **14** [PMID: 37512763 DOI: 10.3390/mi14071452]

27 **Gudlavalleti RH**, Xi X, Legassey A, Chan PY, Li J, Burgess D, Giardina C, Papadimitrakopoulos F, Jain F. Highly Miniaturized, Low-Power CMOS ASIC Chip for Long-Term Continuous Glucose Monitoring. *J Diabetes Sci Technol* 2023: 19322968231153419 [PMID: 36772835 DOI: 10.1177/19322968231153419]

28 **Raikar AS,** Kumar P, Raikar GVS, Somnache SN. Advances and Challenges in IoT-Based Smart Drug Delivery Systems: A Comprehensive Review. *Applied System Innovation* 2023, **6:** 62 [DOI: 10.3390/asi6040062]

29 **Al-Shamsi M**, Amin A, Adeghate E. Vitamin E decreases the hyperglucagonemia of diabetic rats. *Ann N Y Acad Sci* 2006; **1084**: 432-441 [PMID: 17151320 DOI: 10.1196/annals.1372.032]

30 **Amin** **A,** Lotfy M, Mahmoud-Ghoneim D, Adeghate E, Al-Akhras MA, Al-Saadi M, Al-Rahmoun S, Hameed R. Pancreas-protective effects of chlorella in STZ-induced diabetic animal model: insights into the mechanism. *JDM* 2011; **1:** 36-45. Available from: https://www.scirp.org/journal/paperinformation.aspx?paperid=7085

31 **Hamza AA**, Fikry EM, Abdallah W, Amin A. Mechanistic insights into the augmented effect of bone marrow mesenchymal stem cells and thiazolidinediones in streptozotocin-nicotinamide induced diabetic rats. *Sci Rep* 2018; **8**: 9827 [PMID: 29959408 DOI: 10.1038/s41598-018-28029-1]

32 **Cutcliffe C,** Eid JS, Ballard JH, Sickleberger MF, Burger MFS. Methods and compositions for microbial treatment and diagnosis of disorders, JP patent, 2019, JP6868562B2. Available from: https://patents.google.com/patent/JP6868562B2/en

33 **Cutcliffe C,** John S. EidJames H. Bullard, Marcus F. SCHICKLBERGER, Methods and compositions relating to microbial treatment and diagnosis of disorders, 2020, US Patent, US10675312B2. Available from: https://patents.google.com/patent/WO2016070151A8/en

34 **Cutcliffe C,** Eid JS, Altman T, Kolterman OG, Bullard JH. Methods and compositions for treatment of microbiome-associated disorders,2023, US Patent, US11583558B2. Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019046646

35 **Falb D,** Isabella VM, Kotula JW, Miller PF, Rowe SE, Millet Y, Fisher AB. Bacteria engineered to treat metabolic diseases, 2022, US Patent, US20220226395A1. Available from: https://patents.google.com/patent/US20220226395A1/en

36 **Alain DB,** Mark SF, Nigel RB. Compositions and methods for treating metabolic disorders, 2021, JP Patent, JP6581625B2. Available from: https://patents.google.com/patent/JP6581625B2/en?oq=JP6581625B2

37 **Jones A,** Lee J, Jones L, Jones CE. Courtney Ann-Shukdralek Brown, Bethuan-Shukdralek Brown, Beth Erickson, Joshua,Microbiota Recovery Therapy (MRT) Composition, 2021, JP Patent, JP6907288B2. Available from: https://patents.google.com/patent/JP6907288B2/en

38 **Mohan K,** Jerome JS**.** Targeted gastrointestinal delivery of probiotic organisms and/or therapeutic agents, 2020, JP Patent, JP2019077705A. Available from: https://patents.google.com/patent/JP2019077705A/en

39 **Subhadra B.** Devices, systems and methods for the production of humanized gut commensal microbiota, 2019 US Patent, US10246677B2. Available from: https://patents.justia.com/patent/10767157

40 **Chieh JC,** David P, Christian D, Fabrizio A, Catherine M**.** Current Assignee Nestec SA, Gut flora and weight management, 2013, US Patent, US8591880B2. Available from: https://patents.google.com/patent/US20110123501A1/en

41 **Munoz-Garach A,** Diaz-Perdigones C, Tinahones FJ. Gut microbiota and type 2 diabetes mellitus. Endocrinología y Nutrición (English Edition), 2016; **63:** 560-568 [DOI: 10.1016/j.endoen.2016.07.004]

42 **Corb Aron RA**, Abid A, Vesa CM, Nechifor AC, Behl T, Ghitea TC, Munteanu MA, Fratila O, Andronie-Cioara FL, Toma MM, Bungau S. Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a Key Gut Bacterium. *Microorganisms* 2021; **9** [PMID: 33802777 DOI: 10.3390/microorganisms9030618]

43 **Sato J**, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, Kanno R, Tamura Y, Asahara T, Takahashi T, Nomoto K, Yamashiro Y, Watada H. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study. *Sci Rep* 2017; **7**: 12115 [PMID: 28935921 DOI: 10.1038/s41598-017-12535-9]

44 **Salgaço MK**, Oliveira LGS, Costa GN, Bianchi F, Sivieri K. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. *Appl Microbiol Biotechnol* 2019; **103**: 9229-9238 [PMID: 31664483 DOI: 10.1007/s00253-019-10156-y]

45 **Mirjalili M**, Salari Sharif A, Sangouni AA, Emtiazi H, Mozaffari-Khosravi H. Effect of probiotic yogurt consumption on glycemic control and lipid profile in patients with type 2 diabetes mellitus: A randomized controlled trial. *Clin Nutr ESPEN* 2023; **54**: 144-149 [PMID: 36963856 DOI: 10.1016/j.clnesp.2023.01.014]

46 **Hu H**, Luo J, Liu Y, Li H, Jin R, Li S, Wei J, Wei H, Chen T. Improvement effect of a next-generation probiotic L. plantarum-pMG36e-GLP-1 on type 2 diabetes mellitus via the gut-pancreas-liver axis. *Food Funct* 2023; **14**: 3179-3195 [PMID: 36912589 DOI: 10.1039/d3fo00044c]

47 **Sayehmiri F**, Samadian M, Mohamadkhani A, Tafakhori A, Haghighat S, Rahmatian A, Mohammadkhani MA, Fazli HR, Rezaei Tavirani M. Gut Microbiota Modification via Glucagon-like Peptide-1 with Beneficial Neuroprotective Effects. *Middle East J Dig Dis* 2022; **14**: 235-243 [PMID: 36619150 DOI: 10.34172/mejdd.2022.278]

48 **Si J**, Lee G, You HJ, Joo SK, Lee DH, Ku BJ, Park S, Kim W, Ko G. Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. *Comput Struct Biotechnol J* 2021; **19**: 5920-5930 [PMID: 34849196 DOI: 10.1016/j.csbj.2021.10.032]

49 **Cunningham AL**, Stephens JW, Harris DA. Gut microbiota influence in type 2 diabetes mellitus (T2DM). *Gut Pathog* 2021; **13**: 50 [PMID: 34362432 DOI: 10.1186/s13099-021-00446-0]

50 **Nearing JT**, Comeau AM, Langille MGI. Identifying biases and their potential solutions in human microbiome studies. *Microbiome* 2021; **9**: 113 [PMID: 34006335 DOI: 10.1186/s40168-021-01059-0]

51 **Djuric Z**. Dietary approaches for normalizing dysbiosis induced by high-fat, obesogenic diets. *Curr Opin Clin Nutr Metab Care* 2023; **26**: 293-301 [PMID: 36942861 DOI: 10.1097/MCO.0000000000000917]

52 **Li P**, Roos S, Luo H, Ji B, Nielsen J. Metabolic engineering of human gut microbiome: Recent developments and future perspectives. *Metab Eng* 2023; **79**: 1-13 [PMID: 37364774 DOI: 10.1016/j.ymben.2023.06.006]

53 **Bai X,** Huang Z, Duraj-Thatte AM, Ebert MP, Zhang F, Burgermeister E, Liu X, Scott BM, Li G, Zuo T. Engineering the gut microbiome. *Nat Rev Bioeng* **2023:** 1-15 [DOI: 10.1038/s44222-023-00072-2]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 27, 2023

**First decision:** November 14, 2023

**Article in press:**

**Specialty type:** Gastroenterology & hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Amin A, United Arab Emirates **S-Editor:** Liu JH **L-Editor:** Webster JR **P-Editor:**

**Table 1 Representative implanted electronic devices in the intestine for the treatment of type 2 diabetes mellitus**

|  |  |  |  |
| --- | --- | --- | --- |
| **Patent/product name** | **The main ways to exert curative effect** | **Core functional/structural features** | **Ref.** |
| Electroporation for obesity or diabetes treatment | Cause weight loss or control diabetes by reducing the caloric absorption by increasing levels of gut hormones important in appetite regulation and insulin secretion, and/or by reshaping the mucosa of the small intestine | The device can provide an electroporation treatment to modulate the duodenal mucosa, which can also be advanced over a guide wire under endoscopic and/or fluoroscopic guidance | [9] |
| Devices and methods for endolumenal gastrointestinal bypass  | The devices can mimic a Roux-en-Y gastric bypass by effectively reducing stomach volume, bypassing a portion of the stomach and/or small intestine, reducing nutrient absorption in the stomach and/or small intestine | The device can be utilized to support a variety of devices which may be desirably positioned within the stomach or elsewhere in the gastrointestinal system | [10] |
| Methods and systems for glucose regulation  | Up-regulation or down-regulation of various nerves, such as the vagus and its branches. The splanchnic nerve is used to modify the production of GLP-1 and GIP, thereby controlling glucose levels | Applying a neural conduction block to a target nerve at a blocking site with the neural conduction block selected to at least partially block nerve pulses | [11] |
| Treatments for Diabetes Mellitus and Obesity | The stimulation by high-frequency alternating current is selective in blocking slow-conducting, unmyelinated C-fibers, such as those of nociceptive neurons, while minimizing effects on fast-conducting myelinated A-fibers | The ablation may be mechanical, electrical, thermal, radiative, or chemical ablation and may in some cases target a sensory nerve. In highly preferred embodiments, the ablation is a pulsed radiofrequency ablation  | [12] |
| Methods and systems for blocking neural activity in an organ of a subject, preferably in the small intestine or the duodenum  | In preferred embodiments, the invention is directed at endoluminal interventions that block, modulate and/or impact neurohormonal and other signals triggered by food passing through the gastrointestinal tract | Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, *e.g.* microwaves using lasers, the beam being directed along or through a flexible conduit, *e.g.* an optical fiber | [13] |

GLP-1: Glucagon-like peptide-1; GIP: Glucose-dependent insulinotropic polypeptide.

**Table 2 Representative treatment of type 2 diabetes mellitus with intestinal microflora intervention**

|  |  |  |
| --- | --- | --- |
| **Name of the patent**  | **Description** | **Ref.**  |
| Methods and compositions for microbial treatment and diagnosis of disorders | *Akkermansia muciniphila*, *Bifidobacterium adolescentis*, *Clostridium acetobutylicum*, from *Roseburia intestinalis* and the group consisting of any combination Species communities containing one or more microorganisms can be used to treat obesity or metabolic disorders such as T2DM | [32] |
| Methods and compositions relating to microbial treatment and diagnosis of disorders  | The method comprising: Administering a therapeutically-effective amount of a pharmaceutical composition comprising a population of isolated and purified microbes, wherein at least one of said microbes comprises a microbe that encodes for an enzyme selected from the group consisting of: Butyrate kinase, butyrate coenzyme A, butyrate coenzyme A transferase, and any combination thereof, and a pharmaceutically-acceptable carrier | [33] |
| Methods and compositions for treatment of microbiome-associated disorders  | Methods and compositions for modulating short chain fatty acid production in a subject that increase production of butyrate in said subject. The population of isolated and purified microbes comprises a microbe that modulates neurotransmitter production in the subject | [34] |
| Bacteria engineered to treat metabolic diseases | The engineered bacteria comprise one or more gene(s) or gene cassette(s), for the production of molecules which, inter alia, act as metabolic and/or satiety effectors and/or modulators of the inflammatory status and/or are able to convert excess bile salts into non-toxic molecules | [35] |

T2DM: Type 2 diabetes mellitus.